What's happened
Eli Lilly has updated its 2026 revenue guidance upward as sales of Mounjaro and Zepbound propel growth. First-half volumes have outpaced price declines, with Foundayo contributing in pills. The company now expects full-year revenue of $85–87 billion and adjusted EPS of $35.50–$36.50.
What's behind the headline?
Analysis
- The story centers on Lilly’s financial guidance being lifted due to weight-management drug sales, signaling strong demand and the company’s strategic pivot toward a broader obesity portfolio.
- What this means for investors is sustained revenue momentum even as prices decline in some markets, particularly China where reimbursement changes are affecting pricing dynamics.
- Lilly’s emphasis on a future pipeline (retatrutide) and expanded manufacturing capacity suggests a long-term growth trajectory beyond current products.
- The impact on consumers could include more affordable access later if volume growth continues and price reductions are offset by scale, but near-term effects depend on payer policies and competition.
- Forecast: if demand remains robust, Lilly will likely continue to upgrade guidance and pursue further acquisitions to diversify its obesity/diabetes portfolio.
How we got here
Eli Lilly has faced a strong push from obesity and diabetes drugs, led by tirzepatide-based therapies Mounjaro and Zepbound. The company also launched Foundayo and is pursuing expansions in manufacturing and pipelines, alongside a wave of acquisitions aimed at sustaining growth.
Our analysis
Independent reports from the Independent and CNBC show consistent messaging on rising sales of Mounjaro and Zepbound, with Foundayo contributing modestly. CNBC highlights the quarterly figures and forward-looking guidance, while the Independent notes the revenue split and price dynamics in key markets. Both emphasize the company’s focus on long-term growth and production capacity.
Go deeper
- What factors could further boost Lilly’s revenue beyond obesity drugs?
- How might price negotiations in major markets affect future earnings?
- What other assets could Lilly pursue to sustain growth?
More on these topics
-
People’s Republic of China - Country in East Asia
China, officially the People's Republic of China, is a country in East Asia. It is the world's most populous country, with a population of around 1.4 billion in 2019.
-
United States - Country in North America
The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.
-
Eli Lilly and Company - Pharmaceutical company
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Col. Eli Lilly, a